当前位置:
X-MOL 学术
›
Drug. Discov. Today
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
New paradigm for expediting drug development in Asia.
Drug Discovery Today ( IF 7.4 ) Pub Date : 2020-01-08 , DOI: 10.1016/j.drudis.2019.12.013 Iris Rajman 1 , Masaru Hirano 1 , Wataru Honma 1 , Sylvia Zhao 2
Drug Discovery Today ( IF 7.4 ) Pub Date : 2020-01-08 , DOI: 10.1016/j.drudis.2019.12.013 Iris Rajman 1 , Masaru Hirano 1 , Wataru Honma 1 , Sylvia Zhao 2
Affiliation
Some Asian regulators currently require Phase I data in Asians before joining global Phase II/III trials. Here, we discuss inherent limitations of Phase I ethnic sensitivity studies (ESS) to identify potential interethnic differences. We review recent new drug applications (NDAs) for Japan and China to critically assess the value of separate ESSs in Asian populations. Given that the observed value of ESS was limited, we propose a new global drug development paradigm: if relevant safety, pharmacokinetic (PK), and pharmacogenetic (PG) data are available from the original Phase I study population, it might be possible to extrapolate those data to Asian populations for their inclusion in Phase II/III trials, without an ESS. This could help to streamline drug development in Asia while still addressing regulatory requirements.
更新日期:2020-04-20